Minerva Neurosciences Stock Price To Sales

NERV Stock

USD 2.26 0.00 0.00%

Minerva Neurosciences fundamentals help investors to digest information that contributes to Minerva Neurosciences' financial success or failures. It also enables traders to predict the movement of Minerva Stock. The fundamental analysis module provides a way to measure Minerva Neurosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Minerva Neurosciences stock.

		Last Reported	Projected for Next Year
	Price To Sales Ratio	2.09	1.86

Price To Sales Ratio is likely to drop to 1.86 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Minerva Neurosciences Company Price To Sales Analysis

Minerva Neurosciences' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

P/S

MV Per Share

Revenue Per Share

More About Price To Sales | All Equity Analysis

Current Minerva Neurosciences Price To Sales

1.87 X

Most of Minerva Neurosciences' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Minerva Neurosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Minerva Price To Sales Driver Correlations

Understanding the fundamental principles of building solid financial models for Minerva Neurosciences is extremely important. It helps to project a fair market value of Minerva Stock properly, considering its historical fundamentals such as Price To Sales. Since Minerva Neurosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Minerva Neurosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Minerva Neurosciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Common Stock	Current Deferred Revenue	Accounts Payable	Good Will	Short Term Debt	Intangible Assets	Property Plant Equipment	Net Tangible Assets	Short Term Investments	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Long Term Debt Total	Net Invested Capital	Net Working Capital	Capital Stock	Net Receivables
Total Assets		0.76	-0.55	-0.34	0.48	0.96	0.7	0.72	0.63	0.69	0.36	0.39	0.38	0.64	0.72	0.49	0.35	0.63	-0.63	-0.05	-0.05	0.03	-0.06
Total Stockholder Equity	0.76		-0.38	0.26	-0.1	0.66	0.7	0.33	0.19	0.24	0.33	0.83	0.37	0.95	0.68	0.01	0.59	0.24	-0.2	0.55	0.4	0.58	0.46
Net Debt	-0.55	-0.38		0.29	-0.25	-0.55	-0.59	-0.45	-0.6	-0.47	-0.28	-0.11	-0.17	-0.31	-0.08	-0.38	0.17	-0.56	0.5	0.13	0.12	-0.17	0.24
Retained Earnings	-0.34	0.26	0.29		-0.82	-0.42	-0.28	-0.73	-0.7	-0.79	-0.05	0.66	-0.34	0.39	0.0	-0.93	0.52	-0.78	0.83	0.95	0.91	0.64	0.52
Total Liab	0.48	-0.1	-0.25	-0.82		0.58	0.23	0.71	0.74	0.73	0.14	-0.45	-0.01	-0.23	0.24	0.82	-0.22	0.72	-0.75	-0.74	-0.59	-0.59	-0.3
Total Current Assets	0.96	0.66	-0.55	-0.42	0.58		0.67	0.67	0.67	0.65	0.35	0.24	0.29	0.57	0.74	0.6	0.28	0.73	-0.73	-0.15	-0.12	-0.04	-0.07
Common Stock	0.7	0.7	-0.59	-0.28	0.23	0.67		0.63	0.63	0.54	0.29	0.32	0.52	0.6	0.46	0.49	0.09	0.57	-0.59	-0.02	-0.22	0.5	0.33
Current Deferred Revenue	0.72	0.33	-0.45	-0.73	0.71	0.67	0.63		0.74	0.99	0.16	-0.02	0.51	0.14	0.28	0.75	-0.08	0.73	-0.74	-0.5	-0.53	-0.26	-0.17
Accounts Payable	0.63	0.19	-0.6	-0.7	0.74	0.67	0.63	0.74		0.75	0.27	-0.16	0.12	0.08	0.32	0.75	-0.2	0.75	-0.77	-0.55	-0.54	-0.16	-0.26
Good Will	0.69	0.24	-0.47	-0.79	0.73	0.65	0.54	0.99	0.75		0.14	-0.11	0.5	0.06	0.23	0.77	-0.13	0.73	-0.75	-0.58	-0.58	-0.38	-0.33
Short Term Debt	0.36	0.33	-0.28	-0.05	0.14	0.35	0.29	0.16	0.27	0.14		0.32	0.09	0.26	0.26	0.18	-0.16	0.19	-0.23	0.04	-0.01	0.12	0.1
Intangible Assets	0.39	0.83	-0.11	0.66	-0.45	0.24	0.32	-0.02	-0.16	-0.11	0.32		0.11	0.84	0.45	-0.48	0.66	-0.26	0.32	0.85	0.73	0.65	0.52
Property Plant Equipment	0.38	0.37	-0.17	-0.34	-0.01	0.29	0.52	0.51	0.12	0.5	0.09	0.11		0.28	0.27	0.4	0.03	0.31	-0.37	-0.15	-0.4	0.08	-0.08
Net Tangible Assets	0.64	0.95	-0.31	0.39	-0.23	0.57	0.6	0.14	0.08	0.06	0.26	0.84	0.28		0.69	-0.12	0.72	0.1	-0.06	0.66	0.52	0.64	0.46
Short Term Investments	0.72	0.68	-0.08	0.0	0.24	0.74	0.46	0.28	0.32	0.23	0.26	0.45	0.27	0.69		0.22	0.67	0.25	-0.29	0.22	0.19	0.21	0.17
Capital Surpluse	0.49	0.01	-0.38	-0.93	0.82	0.6	0.49	0.75	0.75	0.77	0.18	-0.48	0.4	-0.12	0.22		-0.39	0.91	-0.96	-0.8	-0.83	-0.44	-0.29
Deferred Long Term Liab	0.35	0.59	0.17	0.52	-0.22	0.28	0.09	-0.08	-0.2	-0.13	-0.16	0.66	0.03	0.72	0.67	-0.39		-0.31	0.33	0.67	0.7	0.36	0.3
Short Long Term Debt	0.63	0.24	-0.56	-0.78	0.72	0.73	0.57	0.73	0.75	0.73	0.19	-0.26	0.31	0.1	0.25	0.91	-0.31		-0.98	-0.6	-0.64	-0.31	-0.18
Long Term Debt Total	-0.63	-0.2	0.5	0.83	-0.75	-0.73	-0.59	-0.74	-0.77	-0.75	-0.23	0.32	-0.37	-0.06	-0.29	-0.96	0.33	-0.98		0.66	0.71	0.33	0.21
Net Invested Capital	-0.05	0.55	0.13	0.95	-0.74	-0.15	-0.02	-0.5	-0.55	-0.58	0.04	0.85	-0.15	0.66	0.22	-0.8	0.67	-0.6	0.66		0.92	0.74	0.59
Net Working Capital	-0.05	0.4	0.12	0.91	-0.59	-0.12	-0.22	-0.53	-0.54	-0.58	-0.01	0.73	-0.4	0.52	0.19	-0.83	0.7	-0.64	0.71	0.92		0.53	0.41
Capital Stock	0.03	0.58	-0.17	0.64	-0.59	-0.04	0.5	-0.26	-0.16	-0.38	0.12	0.65	0.08	0.64	0.21	-0.44	0.36	-0.31	0.33	0.74	0.53		0.72
Net Receivables	-0.06	0.46	0.24	0.52	-0.3	-0.07	0.33	-0.17	-0.26	-0.33	0.1	0.52	-0.08	0.46	0.17	-0.29	0.3	-0.18	0.21	0.59	0.41	0.72

Click cells to compare fundamentals

The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Competition

Predict Minerva Neurosciences

Price To Sales Ratio Over Time

Based on the latest financial disclosure, Minerva Neurosciences has a Price To Sales of 1.868 times. This is 91.27% lower than that of the Biotechnology sector and 98.1% lower than that of the Health Care industry. The price to sales for all United States stocks is 83.64% higher than that of the company.

Minerva Price To Sales Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Minerva Neurosciences' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Minerva Neurosciences could also be used in its relative valuation, which is a method of valuing Minerva Neurosciences by comparing valuation metrics of similar companies.

Minerva Neurosciences is currently under evaluation in price to sales category among its peers.

Minerva Neurosciences Current Valuation Drivers

We derive many important indicators used in calculating different scores of Minerva Neurosciences from analyzing Minerva Neurosciences' financial statements. These drivers represent accounts that assess Minerva Neurosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Minerva Neurosciences' important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	277.4M	95.5M	34.2M	8.5M	40.0M	38.0M
Enterprise Value	256.3M	70.3M	(26.5M)	46.1M	81.1M	127.3M

Minerva Neurosciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Minerva Neurosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Minerva Neurosciences' managers, analysts, and investors.

Environmental

Governance

Social

Minerva Fundamentals

	Return On Equity	-6.75
	Return On Asset	-0.29
	Current Valuation	(11.49 M)
	Shares Outstanding	6.99 M
	Shares Owned By Insiders	22.26 %
	Shares Owned By Institutions	30.47 %
	Number Of Shares Shorted	23.38 K
	Price To Earning	69.58 X
	Price To Book	2.68 X
	Price To Sales	1.87 X
	Gross Profit	(16.84 M)
	EBITDA	(21.69 M)
	Net Income	(30.01 M)
	Cash And Equivalents	40.22 M
	Cash Per Share	7.53 X
	Total Debt	82.02 M
	Debt To Equity	0 %
	Current Ratio	20.41 X
	Book Value Per Share	(3.10) X
	Cash Flow From Operations	(14.78 M)
	Short Ratio	0.96 X
	Earnings Per Share	(0.45) X
	Target Price	5.0
	Beta	0.17
	Market Capitalization	15.04 M
	Total Asset	56.9 M
	Retained Earnings	(396.82 M)
	Working Capital	38.66 M
	Current Asset	33.48 M
	Current Liabilities	5.32 M
	Net Asset	56.9 M

About Minerva Neurosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Minerva Neurosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Minerva Neurosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Minerva Neurosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Minerva Stock Analysis

When running Minerva Neurosciences' price analysis, check to measure Minerva Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neurosciences is operating at the current time. Most of Minerva Neurosciences' value examination focuses on studying past and present price action to predict the probability of Minerva Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Minerva Neurosciences' price. Additionally, you may evaluate how the addition of Minerva Neurosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC